




CREIGHTONS_{plc}

Interim Results April – September 2025
19 November 2025



QUALITY • SERVICE • INNOVATION





AGENDA



01

**Company Introduction
and Highlights**

02

Financial Review

03

Strategy Update

04

Summary

QUALITY • SERVICE • INNOVATION



ABOUT CREIGHTONS AND HIGHLIGHTS



ABOUT CREIGHTONS



Vision:

Best in Class Consumer–Centric Beauty and Wellness Product business

What We Do:

- Ideation, Design, Develop, Manufacture, Source and Distribute
- High Quality Beauty, Personal Care and Wellness products
- Broad range of categories including; Skincare, Haircare, Bath + Body, Self Tan, Babycare, Male Grooming, SPF formulations and Fragrance/Body Mists

How We Do It and Who For:



- Full-service supply, concept to distribution
- Major retails chains of all types and brands

Route to market:

- 3 revenue streams: Private Label, Owned Brands, Contract Manufacturing
- UK and International Markets

The Team:

- 380 employees over two manufacturing sites in the UK
- Head Office Peterborough, Cambridgeshire and Tiverton, Devon
- Design, Brand + Product Development, R+D, Packaging, Purchasing, Supply Chain/Forecasting, Technical Compliance, Manufacturing and Customer Service/Distribution



Industry Leaders in Private Label

Brand Owners and Creators

Award-Winning Innovation & Exceptional Quality

Flexible, Agile, Scalable, Full-Service Solutions

Ethical & Sustainable – Proudly SEDEX Registered

Passionate and skilled team committed to the industry

QUALITY • SERVICE • INNOVATION



**Award
Winning**



**Performance
Products**



**Innovative
Solutions**



**Global
Appeal**

FINANCIAL HIGHLIGHTS



£27.2m

Comparable Performance
(2024 : £27.1m)

Revenue

44.7%

Improved by 0.7%
(2024: 44.0%)

Gross Margin

£1.45m

NI Increased Labour Cost Impact
(2024: £1.70m)

Operating Profit

£2.2m

£0.4m NLW and NIC + £0.2m
people investment
(2024: £2.5m)

EBITDA

£2.9m

Increased by £1.4m
Working Capital Management
(2024: £1.5m)

Net Cash on Hand

1.49p

Reduction in PBT
(2024: 1.61p)

Diluted EPS

OPERATIONAL HIGHLIGHTS



1

Improved Gross profit margin of 70 bps to **44.7% (2024: 44.0%)** on marginally higher revenue of **£27.2m (2024: £27.1m)** owing to cost reduction, product mix and manufacturing efficiencies.

2

Distribution costs decreased by **4.1% to £1.3m (2024: £1.4m)**, representing **4.9% of revenue (2024: 5.2%)**, reflecting the focus on operational efficiency and cost control.

3

Administration costs have increased by **6.4% to £9.4m (2024: £8.8m)**, reflecting the impact of the rise in the cost of the national living wage and national insurance costs.

4

Inventory levels remained comparable at **£8.7m (2024: £8.7m)**, demonstrating disciplined stock management

5

Investment of £0.2m of indirect labour to support strategic revenue drive in private label growth, international sales expansion and launch to market of 'fast follow' product in brand



REVENUE HIGHLIGHTS

Private Label	Brands	Contract Manufacturing
+15.4%	-2.2%	-50.5%
£16.6m	£8.7m	£1.9m
(2024: £14.4m)	(2024: £8.9m)	(2024: £3.8m)

Private Label

- **Customers** : Two newly acquired last year contributing to growth
- **Category Diversification** : Fragrance driving, SPF evolving
- **Customer Partnerships** : Superdrug Own Label Supplier Of the Year 2025
- **Team Investment** : additional team members and internal development


Brands

- **Must Win Brands** :
 - Emma Hardie impact by No.1 customer’s cyber attack, no orders for 4 months
 - Revenue gains in The Curl Company and Tzone brands
 - Margin gains in Feather + Down and Emma Hardie
- **Fast Follow**: Driving growth in U.S. off-price sector
- **Team Investment** : International Sales, Fast Follow, 3rd Party Sourcing

Contract Manufacturing

- **Revenue Decline** : Key customer delayed new launch from early 2026 to 2027 coupled with reducing forecasts for 2025
- No investment or new business priority this year

Group Sales by Revenue Stream





FINANCIAL REVIEW



REVENUE STREAMS



Revenue for the interim period was £27.2m (2024: £27.1m), an increase of 0.5%




Private label continues positive sales momentum



Branded sales challenged but historic decline stabilised due to NPD, team investment and ‘fast follow’ strategy



Challenging market for Contract continues to reduce performance



GROSS PROFIT MARGIN



1

Sept 2022:

Increase in direct costs due to global supply chain and inflationary pressures

2

FY 2023 onwards:


GPM has been on an increasing trend

3

Sept 2025:

GPM increased 0.7% against Sept 2024 last year

Gross profit margin - %



OPERATING PROFIT BEFORE EXCEPTIONALS



Operating profit for H1 in FY26 remains positive despite the challenging economic backdrop

Administrative costs have increased by 6.4% to £9.4m (2024: £8.8m)

NLW and NIC increased indirect labour by £0.2m.


Investment to drive sales growth further increased indirect labour by £0.2m.

Cost saving initiatives reduced overhead costs by £0.1m.


Distribution costs have decreased by 4.1% to £1.3m (2024: £1.4m)

A change in the sales mix has contributed to a reduction in outbound freight costs.

Operating profit before exceptionals - £m



CASH FLOW MOVEMENT (£m)



WORKING CAPITAL



Stock levels comparable at £8.7m to September 2024

Efficient use of working capital: Inventory is moving at a healthy rate, reducing the amount of cash tied up in stock.



Stock turn (closing stock) is 3.4 times (2024 3.4 times)

Continue to monitor inventory levels closely to maintain operational efficiency, customer service level performance and avoid excess holding costs.



Trade debtor days 67 days (2024: 65 days)

Debtors increased by £0.1m compared to September 2024 and £2.2m compared to March 2025.

The movement since FY25 reflects timing of sales activity in Q2 2026 vs Q4 2025



Creditors increased by £1.1m compared to March 2025

Reflecting timing of supplier payments.

We are actively exploring extended supplier payment terms to assist with working capital.



PASSIONFLOWER

Passionflower extract has calming skin benefits and can aid relaxation and help you to get a more restful night's sleep.



MAGNESIUM


Optimal levels of magnesium have a beneficial impact on many of the body's functions including sleep.



STRATEGY UPDATE



STRATEGIC PILLARS



Build
Brands

Grow
Private Label
Share

R+D
Focused
Business

Maintain
Core Stable
Foundations

Well Invested
Manufacturing
&
Capabilities

Develop
Teams
and
People

Deliver
for
Shareholders



GROW PRIVATE LABEL SHARE

HOW WE DO IT



Customer Partnerships

Work with the best-in-class retailers



R+D Category Development

Innovative Solutions



UK Supply

Retain the leading position in UK supply



Global Sourced

Add via sourced finished product




Margin Positive

Driving Focus

Customers


Categories

Product



GROW PRIVATE LABEL SHARE

PRIORITIES FOR GROWTH



BUILD BRANDS



HOW WE DO IT

Must Win Brands



Fast Follow



PRIORITIES FOR GROWTH

Channel Expansion

International

- Additional resource implemented

Travel

- Feather & Down First trial cruise executed
- Phase two; three additional trial cruises early 2026

Off Price USA

- Growing with 'Fast Follow' activity

Differentiation

Fast Follow

- Initial concepts created, currently presenting to market, sales impact commences H1 2026

Product Differentiation

- 3rd Party Sourced Product positive momentum
First products to land for H1 2026 sales

Brand Creation


New Brand Launch Spring/Summer 2026

- Premium brand extension to Feather + Down launching Spring 2026

Brand Relaunch + Repositioning

- Completed strategic review of Janina (whitening oral care) working in partnership with key leading UK retailer

FAST FOLLOW



Fast Follow

Accelerated concept
ideation

Working with key
strategic retailers

3rd Party Sourcing
aiding speed to
market

Multi-Category

Bath + Shower

Skincare

Bodycare


Haircare

Body Mists

R+D FOCUSED



HOW WE DO IT



'Fast Follow' Strategy
Speed to Market
Trend Led



Cutting edge and
trend ingredients,
Product textures
and formats



Evaluation of
materials more
sustainable products



Technical and
Legislative
Compliance

PRIORITIES FOR GROWTH

New Team Structure

Innovation Driven
Revenue Opportunity Focused
Smarter Working
Speed to Market

Formulation Database

Maximising expertise
Improving Speed to Market
Focus on 'Fast Follow' and 'White Space' opportunities

Digital Transformation

Invested in leading cloud-base R+D cost and management platform
Improved access, visibility and speed



WELL INVESTED MANUFACTURING + CAPABILITIES



HOW WE DO IT

Investment Priorities

Increase capacity

Increase flexibility

Improve labour efficiency and utilisation

Extend capabilities

AI & automation solutions to improve processes & efficiencies

PRIORITIES FOR GROWTH

01

WMS system

Labour and operational efficiency and accuracy gains

Operational Sept 2025

03

Fragrance line upgrade

Category Diversification for Revenue growth

Phase 1 complete.
Phase 2 during H2

02

Digital Transformation

Evocon (live production data) and Manage Artworks implementation commenced.

Due to complete early H2.

04

New ERP system

Reduce business risk by replacing current legacy system

Scoped and short list underway

05

Capacity Focus

Facilitating growth

Targeted plan of upgrades and replacements to maximise capacity



SUMMARY

- Resilient financial performance with improving gross profit margins, despite material increased labour costs
- Private Label customer partnerships and category diversification driving growth
- Continuing to advance strategically and operationally
- Investment in Growth
 - ❑ Refocusing Brand approach
Fast Follow initiatives and International focus
 - ❑ 3rd Party Sourced Product
Add to and complement both Brand and Private Label ranges
 - ❑ Extending Teams
Investment in people in both Private Label and Brand Fast Follow to drive growth
 - ❑ Restructured R+D team
Deliver improved speed to market, maximise existing development investments and joined up approach with commercial teams
- Investment in Efficiencies and Capabilities
 - ❑ Digital Transformation projects momentum
 - ❑ Fragrance filling line investment to compete
 - ❑ Capacity and labour efficiency focused plan of machinery upgrades to deliver on growth

DISCLAIMER



The information contained in these slides and any accompanying verbal presentation, any question-and-answer session and any document or material distributed at or in connection with the verbal presentation (together, the “Presentation”) have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”). Reliance upon this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. If any person is in any doubt as to the contents of this Presentation, they should seek independent advice from a person who is authorised for the purposes of FSMA and who specialises in advising on investments of this kind. This Presentation is being supplied to you solely for your information and does not purport to contain all information that may be required to evaluate Creightons plc (the “Company”). This Presentation has been prepared by, and is the sole responsibility of, the Company. The Presentation has not been verified by the Company’s lawyers, but the directors of the Company believe they have taken all reasonable care to ensure that the facts stated herein are true to the best of their knowledge, information and belief.

This Presentation does not constitute, or form part of, an admission document, listing particulars, a prospectus or a circular relating to the Company, nor does it constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company nor shall it or any part of it, or the fact of its distribution, form the basis of, or be relied upon in connection with, or act as any inducement to enter into any contract. Any investment in shares in the Company should only be made by you on the basis of definitive documentation in final form (which may contain different information from the information contained in this Presentation), and you own judgment as to the merits of the suitability of the shares for your purposes, having taken all such professional advice you consider necessary or appropriate in the circumstances.

No reliance may be placed for any purpose whatsoever on the information or opinions contained in this Presentation or on its completeness, accuracy or fairness thereof, nor is any responsibility accepted for any errors, misstatements in, or omission from, this Presentation or any direct or consequential loss however arising from any use of, or reliance on, this Presentation or otherwise in connection with it.

This Presentation may not be reproduced or redistributed, in whole or in part, to any other person, or published, in whole or in part, for any purpose without the prior consent of the Company. The contents of this Presentation are confidential and are subject to updating, completion, revision, further verification and amendment without notice.

Neither this Presentation nor any copy of it should be distributed, directly or indirectly, by any means (including electronic transmission) to any persons with addresses in the United States of America (or any of its territories or possessions) (together, the “US”), Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa, or to any corporation, partnership or other entity created or organised under the laws thereof, or in any other country outside the United Kingdom where such distribution may lead to a breach of any legal or regulatory requirement. The recipients should inform themselves about and observe any such requirements or relationship. The Company’s ordinary shares have not been, and are not expected to be, registered under the United States Securities Act 1933, as amended, (the “US Securities Act”) or under the securities laws of any other jurisdiction, and are not being offered or sold, directly or indirectly, within or into the US, Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa, or to, or for the account or benefit of, any US persons or any national, citizen or resident of the US, Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa, unless such offer or sale would qualify for an exemption from registration under the US Securities Act and/or any other applicable securities laws.

This Presentation or documents referred to in it contain forward-looking statements. These statements relate to the future prospects developments and business strategies of the Company and its subsidiaries (the “Group”). Forward-looking statements are identified by the use of such terms as “believe”, “could”, “envisage”, “estimate”, “potential”, “intend”, “may”, “plan”, “will” or the negative of those, variations or comparable expressions, including references to assumptions. The forward-looking statements contained in this Presentation are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. If one or more of these risks or uncertainties materialises, or if underlying assumptions prove incorrect, the Group’s actual results may vary materially from those expected, estimated or projected. Given these risks and uncertainties, potential investors should not place any reliance on forward-looking statements. These forward-looking statements speak only as at the date of this Presentation. The Company is under no obligation to, and expressly disclaims any intention to, update or revise such forward-looking statements, estimates or projections.